European Regulatory Breakthrough Positions Cellectar Biosciences for Growth

Cellectar Biosciences has achieved a critical regulatory milestone that could pave the way for European commercialization of its cancer therapeutic iopofosine I 131 by 2027. The company received confirmation from the European Medicines Agency’s Scientific Advice Working Party that it can pursue conditional marketing authorization for the treatment of refractory Waldenstrom Macroglobulinemia.

The pathway toward European approval gains strength from impressive clinical trial results. In the CLOVER WaM Phase 2 study, iopofosine I 131 demonstrated substantial therapeutic potential:

• High Response Rates: Treatment achieved an overall response rate of 83.6%
• Significant Clinical Benefit: Among heavily pretreated patients, 58.2% reached major response criteria
• Accelerated Pathway Designation: The therapy previously received PRIME designation from European... Read more...